Prognostic importance of dna ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1178-1184

  Pradhan, M ^a,b   Abeler, V M ^a   Danielsen, H E ^a,b   Sandstad, B ^c   Trope C G ^a,b   Kristensen, G B ^a   Risberg, B Å ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

DNA index; DNA ploidy; EAC; Endometrial carcinoma; Image cytometry

Indexed keywords

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIPLOIDY; DNA DETERMINATION; DNA INDEX; ENDOMETRIOID CARCINOMA; FEMALE; GENETIC PARAMETERS; HUMAN; HUMAN TISSUE; IMAGE CYTOMETRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PLOIDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; TETRAPLOIDY;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CARCINOMA, ENDOMETRIOID; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; MITOTIC INDEX; NEOPLASM STAGING; PLOIDIES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84860456239     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr368     Document Type: Article

References (34)

1. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004; 35: 649-662.
2. Abeler VM, Kjørstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991; 67: 3093-3103.
3. Lundgren C, Auer G, Frankendal B et al. Prognostic factors in surgical stage I endometrial carcinoma. Acta Oncol 2004; 43: 49-56.
4. Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS 2002; 110: 673-689.
5. Susini T, Amunni G, Molino C et al. Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: DNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors. Cancer 2007; 109: 882-890.
6. Terada K, Mattson D, Goo D, Shimizu D. DNA aneuploidy is associated with increased mortality for stage I endometrial cancer. Gynecol Oncol 2004; 95: 483-487.
7. Wik E, Trovik J, Iversen OE et al. Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. Am J Obstet Gynecol 2009; 201: 603-607.
8. Lindahl B, Masback A, Persson J et al. Adenocarcinoma corpus uteri stage I-II: results of a treatment programme based upon cytometry. Anticancer Res 2009; 29: 4731-4735.
9. Mangili G, Montoli S, De Marzi P et al. The role of DNA ploidy in postoperative management of stage I endometrial cancer. Ann Oncol 2008; 19: 1278-1283.
10. Hö gberg T, Fredstorp-Lidebring M, Alm P et al. A prospective population-based management program including primary surgery and postoperative risk assessment by means of DNA ploidy and histopathology. Adjuvant radiotherapy is not necessary for the majority of patients with FIGO stage I-II endometrial cancer. Int J Gynecol Cancer 2004; 14: 437-450.
11. Zaino RJ, Davis AT, Ohlsson-Wilhelm BM, Brunetto VL. DNA content is an independent prognostic indicator in endometrial adenocarcinoma. A Gynecologic Oncology Group study. Int J Gynecol Pathol 1998; 17: 312-319.
12. Baak JP, Snijders W, van Diermen B et al. Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in international Federation of gynecology and obstetrics stage 1 and 2 endometrial carcinoma. J Clin Oncol 2003; 21: 4214-4221.
13. Nordström B, Strang P, Lindgren A et al. Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications? Int J Gynecol Pathol 1996; 15: 191-201.
14. Santala M, Talvensaari-Mattila A. DNA ploidy is an independent prognostic indicator of overall survival in stage I endometrial endometrioid carcinoma. Anticancer Res 2003; 23: 5191-5196.
15. Silverberg SG, Kurman RJ, Nogales F et al. Tumours of uterine corpus. In Tavassoli FA, Devilee P (eds): World Health Organization Classification of Tumours: Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press 2003; 218-232.
16. Sorbe B, Risberg B. Prognostic importance of the nuclear proteins p53 and Rb in conjunction with DNA, nuclear morphometry and grading in endometrial carcinoma. Int J Gynecol Cancer 1997; 7: 34-41.
17. Ørbo A, Rydningen M, Straume B, Lysne S. Significance of morphometric, DNA cytometric features, and other prognostic markers on survival of endometrial cancer patients in northern Norway. Int J Gynecol Cancer 2002; 12: 49-56.
18. Pradhan M, Abeler VM, Danielsen HE et al. Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod Pathol 2006; 19: 1227-1235.
19. Mariani A, Sebo TJ, Webb MJ et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev 2003; 27: 434-441.
20. Lim P, Aquino-Parsons CF, Wong F et al. Low-risk endometrial carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators. Gynecol Oncol 1999; 73: 191-195.
21. Lundgren C, Auer G, Frankendal B et al. Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma. Int J Gynecol Cancer 2002; 12: 110-118.
22. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004; 444: 213-223.
23. Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 (Suppl 1): S105-S143.
24. Abeler VM, Kjørstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol 1991; 40: 207-217.
25. Abeler VM, Kjørstad KE, Berle E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. Int J Gynecol Cancer 1992; 2: 9-22.
26. Atkin NB. Frequency of hyperdiploid chromosome complements in endometrioid tumors of the endometrium whereas similar tumors in the ovary tend to show hypodiploidy: a significant difference that may not be distinguishable by flow cytometry of DNA content. Cytogenet Genome Res 2002; 97: 39-42.
27. Abeler VM, Vergote IB, Kjørstad KE, Tropé CG. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer 1996; 78: 1740-1747.
28. Benito V, Lubrano A, Arencibia O et al. Pure papillary serous tumors of the endometrium: a clinicopathological analysis of 61 cases from a single institution. Int J Gynecol Cancer 2009; 19: 1364-1369.
29. Kristensen GB, Kildal W, Abeler VM et al. Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Ann Oncol 2003; 14: 1494-1500.
30. Pradhan M, Abeler VM, Davidson B et al. DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens. Int J Gynecol Pathol 2010; 29: 572-578.
31. Susini T, Rapi S, Massi D et al. Preoperative evaluation of tumor ploidy in endometrial carcinoma: an accurate tool to identify patients at risk for extrauterine disease and recurrence. Cancer 1999; 86: 1005-1012.
32. Podratz KC, Wilson TO, Gaffey TA et al. Deoxyribonucleic acid analysis facilitates the pretreatment identification of high-risk endometrial cancer patients. Am J Obstet Gynecol 1993; 168: 1206-1213.
33. Kodama S, Kase H, Tanaka K, Matsui K. Multivariate analysis of prognostic factors in patients with endometrial cancer. Int J Gynaecol Obstet 1996; 53: 23-30.
34. Kærn J, Wetteland J, Tropé CG et al. Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer. Cytometry 1992; 13: 314-321.